Clinical Trial Update: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial investigating eribulin mesylate and everolimus in triple-negative metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• HER2 Neu Negative Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Everolimus (everolimus)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Status: COMPLETED | Results posted: 2022-04-25